News Hub | News Direct

Cardano, Raboo and Ordi are Trending This Week, Find Out Why

Total Media

The crypto market is buzzing this week. Cardano's got everyone talking, Raboo's making headlines, and Ordi's emerging as a dark horse. But what's the deal with all this excitement? Buckle up, crypto enthusiasts, because we're about to dive into the factors propelling these projects to the top. Cardano and Ordi have got their loyal fans, but Raboo's the one stealing the show with a mind-blowing 60% surge since launch and whispers of a 100x explosion from analysts. Read on to discover why these three currencies are trending and what makes Raboo the hottest name in crypto right now. Cardano's trend this week and its causes Cardano (ADA) has always been present in the crypto news arena, and recently, it has been back in the news again. As of June 17, 2024, it is being traded around $0.402. But it's not just about the price; the attention that is paid to Cardano is mostly focused on the next steps in its evolution. On June 9, Charles Hoskinson, creator of Cardano, announced on X that Cardano’s upcoming Chang fork is approaching quickly and that Cardano Node will likely reach version 9.0 this month. This update will improve the network for executing smart contracts. This is a significant development in Cardano and can place it at the same level as some of the leading Smart Contracts platforms, such as Ethereum. Cardano has many enthusiasts waiting for the actualisation of the proposed technology, and with this update, Cardano may pave itself as one of the great blockchains. While some analysts remain bullish about Cardano, we have seen that the future of this coin is still undecided, and only time will tell whether it will bring hope to its army of investors. The recent trend of Ordi Ordi (ORDI) is the dark horse newcomer shaking things up in the crypto world. While it may not be a household name yet, ORDI has recently seen a surge in interest. As of June 17, 2024, ORDI is trading around $41.80. But what's behind this uptick in attention? One factor could be Ordi’s new partnership with BidoFinance, a Bitcoin staking protocol, which has garnered significant community interest and contributed to the token's breakout. Ordi's unique value proposition as an "Inscriptions" cryptocurrency is also generating interest. This is where inscriptions are helpful; users can write informative text on the Bitcoin blockchain, and the information can never be erased, which paves the way for owning digital art or having a decentralised way of storing particular data. Altogether, Ordi is quite a young project, but its potential and new essential features alongside new partnerships attracted attention. On one hand, market gurus have undertaken forecasts that Ordi is a coin with the potential to grow in the future, while on the other hand, there are sceptics who are of the contrary opinion. Only time will tell if Ordi can live up to the hype, but one thing's for sure: it is a coin we should watch. Raboo: The memecoin with a mastermind Cardano and Ordi might be grabbing headlines, but the real party is happening in the meme coin realm, and Raboo is the guest of honour. This isn't your average doge-faced token chasing fleeting trends. Raboo's more like a meme maestro conducting an orchestra. Raboo's presale has been a smash hit, bringing in over a cool $1.7 million and rocketing a mind-blowing 60% since the presale started. But Raboo's not just about the hype. They've got the tech chops to back it up. Raboo's AI-powered meme generator lets you easily unleash your inner creator and craft viral content. Also, Raboo's "Post-to-Earn" platform rewards you for your humour. Experts are predicting a meteoric rise for Raboo, with some whispers of a 100x surge. With its innovative features and gamified social experience (coined SocialFi), Raboo is poised to become a memecoin leader. This is your chance to join the Raboo revolution. While Cardano and Ordi ponder their next moves, Raboo's already started the party. Get in early and make massive profits. Conclusion Hold onto your hats, crypto enthusiasts; this week's market is a rollercoaster of trending tokens. Cardano's loyal community is buzzing about upcoming smart contract features, while Ordi's partnership with a Bitcoin staking protocol has investors talking. But if you're looking for the most exciting project with a sprinkle of meme magic, Raboo is the name on everyone's lips. With experts predicting a 100x surge and the potential to become a top-tier meme coin, Raboo is an opportunity you don't want to miss. Don't wait on the sidelines; dive into the Raboo revolution and see where it takes you! This meme coin with a brain might be the smartest investment you make all year. You can participate in the Raboo presale here Telegram: https://t.me/RabootokenPortal Twitter: https://twitter.com/Raboo_Official Contact Details Total Media Solutions media@Totalsolutionspr.io

June 17, 2024 09:05 AM Eastern Daylight Time

Image

Hoffman Financial Group Joins Forces with AmeriLife’s Brookstone Capital Management

AmeriLife

Brookstone Capital Management (“Brookstone”), a leading, SEC-Registered Investment Advisory (RIA) firm and affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has partnered with Hoffman Financial Group, a nationally recognized financial planning firm based in Atlanta. Per the agreement, terms of the deal were not disclosed. “We’re excited to partner with the Hoffman team. This collaboration will only strengthen both organizations and continue to provide best-in-class solutions for them and all the clients they serve,” said Dean Zayed, CEO of Brookstone Capital Management. “Additionally, this partnership underscores Brookstone’s ongoing investment and commitment to our advisors and our goal to be the leader at the intersection of insurance and securities.” “Hoffman Financial Group is a premier financial services firm – Chris and his team have created something special that we are excited to be a part of,” added Darryl Ronconi, president of Brookstone Capital Management. “With a broader relationship with Brookstone and AmeriLife, our goal is to help continue to accelerate their significant growth by providing them with even more resources and support.” Founded in 2011, Hoffman Financial Group is a comprehensive financial and retirement planning firm with one goal in mind: to be the go-to financial advisor for individuals wanting to retire. The firm offers a completely hands-on approach to retirement planning and a full suite of wealth management offerings, including investment management, 401(k) and IRA rollovers, tax planning, and more through its eight investment advisor representatives. Hoffman Financial Group has applied this high-touch approach to unique offerings such as Her Wealth Her Way ®, designed specifically to help women retire with comfort, confidence, and class. Hoffman Financial Group is also incredibly active in the media, bringing its expertise on money management to viewers of The Financial Edge on Atlanta’s CBS 46 and ABC’s Good Morning America Weekend every Sunday morning, and to listeners of Money Unleashed on Atlanta’s 95.5 WSB every Sunday afternoon. Additionally, the firm is an Official Partner of the University of Georgia Bulldogs ® and, most recently, was named Official Financial Advisor of former Bulldog and NFL player Brock Bowers, partnerships that have cemented Hoffman Financial Group as a leading financial services company alongside two distinguished names in collegiate sports. “I couldn’t be more excited to partner and expand our relationship with Brookstone,” said Chris Hoffman, founder of Hoffman Financial Group. “They are the best partner to take us to the next level. The entire team is thrilled about the opportunity of aligning Hoffman Financial Group with the extensive resources and talent that they offer.” Now, as part of the AmeriLife family of companies, Hoffman Financial Group will enjoy broad access to best-in-class platforms, tools, resources, and an expansive product portfolio to move quickly into new markets, accelerate production, and drive the firm’s growth for years to come. “Chris Hoffman has built a powerhouse brand and business that is reshaping retirement planning for America’s retirees,” said Mike Vietri, Chief Distribution Officer for AmeriLife Wealth Group. “We’re incredibly excited for Hoffman Financial Group to join forces with Brookstone as part of AmeriLife Wealth Group, and look forward to integrating their unique approach, expertise, and leadership into our fast-growing distribution platform.” ### About Hoffman Financial Group Hoffman Financial Group is a leading financial planning firm based in Atlanta, Ga. With a personalized approach coupled with highest standards of financial advisory services, the firm specializes in principal protection, income planning, wealth accumulation, legacy planning, and more. For more information, visit HoffmanCorporation.com. About Brookstone Capital Management Founded in 2006, Brookstone Capital Management (BCM) is an SEC-Registered Investment Advisory firm with over $9.5B in Assets Under Management (AUM), providing fee-based investment management services through its network of more than 750 financial advisors and firms. Brookstone is an innovator and industry leader and empowers independent financial advisors of all sizes to scale their business by providing access to a Turnkey Asset Management Platform (TAMP) along with a dedicated team to support every aspect of an advisor’s practice. Visit BrookstoneCM.com for more information. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as a leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado media@amerilife.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

June 17, 2024 09:00 AM Eastern Daylight Time

ATFX Integrates PriceOn™ from TraderTools to Enhance Global Group Trading Efficiency

500NewsWire

Hong Kong, June. 17, 2024 – ( 500NewsWire ) — ATFX has announced a significant enhancement to its global trading infrastructure with the integration of PriceOn™ from TraderTools. ATFX is set to revolutionize how the firm manages trading flows from current institutional and retail clients, ultimately improving pricing and execution experiences, alongside attracting new clients with data and risk metrics driven confident, unique pricing. Enhancing Client Experience PriceOn will empower ATFX to manage trading flows more effectively and efficiently, ensuring clients benefit from superior execution and competitive pricing. The advanced technology underpinning PriceOn, which leverages artificial intelligence and sophisticated algorithms, is designed to handle complex client flows seamlessly. This capability will enable institutional clients flows to match with a broad range of retail client flows, (and vice-versa) even those with challenging characteristics, without compromising execution performance. Advanced Technology and Client-Centric Approach PriceOn’s AI-based algorithms represent the cutting edge of trading technology, providing precise and strategic execution that maximizes profitability for clients. Unlike traditional models, this partnership focuses on delivering enhanced returns for ATFX’s global clients. Building an Integrated Trading Ecosystem By integrating PriceOn, ATFX is bridging the gap between retail and institutional trading environments, fostering a cohesive ecosystem that supports diverse global trading needs. This strategic move aligns with ATFX’s broader project of creating an integrated trading environment where different client types can interact seamlessly. Client-Centric Vision As Chairman of ATFX, Joe Li expressed his excitement about the integration of PriceOn from TraderTools to enhance ATFX pricing. He stated, “This strategic partnership will revolutionize our pricing capabilities and provide our clients with more competitive and accurate pricing. We are committed to constantly adapting and improving our services to meet the ever-evolving needs of our clients.” The integration of PriceOn into the ATFX platform is the latest milestone that underscores the company’s dedication to innovation and excellence in trading solutions. Acquisition of regulatory licenses in South Africa and Australia, hiring of key senior industry executives and now the integration of PriceOn confirm ATFX’s position as a vanguard of the industry. This strategic enhancement will not only improve pricing but also provide clients with a more efficient and profitable trading experience. About ATFX ATFX is a leading global fintech broker with a local presence in 23 locations and licenses from regulatory authorities, including the UK’s FCA, Cypriot CySEC, UAE’s SCA, Australian ASIC, and South African FSCA. With a strong commitment to customer satisfaction, innovative technology, and strict regulatory compliance, ATFX provides exceptional trading experiences to clients worldwide. For further information on ATFX, please visit ATFX website https://www.atfx.com. Contact Details ATFX sales.uk@atfx.com

June 17, 2024 08:58 AM Eastern Daylight Time

Image

Market Forecasts Hint At A Lithium Revival: Could This Be A Golden Opportunity For Argentina Lithium (OTCQX: LILIF) And Other Miners?

Benzinga

By James Blacker, Benzinga The global lithium market has seen a precipitous price fall over the last year and a half, from a peak of over $80,000 per ton in November 2022 to around $15,000 currently. Recent forecasts, however, suggest that the market is poised for a turnaround as supply/demand dynamics become more favorable, presenting a unique opportunity for investors to gain exposure to the market through miners such as Argentina Lithium (OTCQX: LILIF), Albemarle (NYSE: ALB) and Arcadium Lithium (NYSE: ALTM). Has Lithium Finally Bottomed Out? One of the main reasons for this price crash was that mining companies ramped up production in anticipation of booming demand for electric vehicles (EVs) that never materialized as economic uncertainty made consumers more cautious. This left a surplus of lithium on the market, which placed downward pressure on prices. However, S&P Global anticipates that there will be a global lithium deficit of some 4,000 tons by 2027, with global demand set to hit 1.87 million tons, up from 884,000 tons in 2023. In the U.S., demand for lithium is predicted to grow 487% by 2030 to nearly 412,000 tons by 2030. Furthermore, the next few years could see substantial growth in the battery EV market. Grand View Research forecasts the market will grow at a CAGR of 33.6% from 2024 to 2030 to reach nearly $9 trillion. All this points to a potential correction in the price of lithium as demand looks set to outpace supply with increasing lithium consumption, particularly in the EV sector. Argentina Lithium: A Promising Contender Against this backdrop, one company to keep an eye on is Argentina Lithium, a miner focused on acquiring lithium projects in Argentina and advancing them toward production. The company has projects covering over 67,000 hectares (166,000 acres) in the Lithium Triangle in South America, which produces about half of the world's lithium and contains around 60% of known global lithium reserves. Argentina Lithium’s growth trajectory has been significantly bolstered by a $90 million investment in Argentina peso equivalent by Stellantis N.V., one of the Big Three American automakers looking to make its mark in the electric vehicle arena. Argentina Lithium recently announced promising exploration results from its Rincon West Project, where brine samples collected from the 12 th exploration hole were found to contain from 322 to 371 mg/l of lithium. The company said it is now beginning its 13 th exploration hole and a second rig is beginning drilling of the first deep pumping well. The Rincon West project covers over 5,000 hectares (12,999 acres) at the Rincon Salar in Argentina’s Salta Province. It is notable for its significant lithium concentrations and proximity to other major development projects. “Our twelfth hole demonstrates a long interval of impressive lithium values in porous host lithologies. Thus far, our drilling at Rincon West demonstrates a continuous aquifer of concentrated lithium brines over an extensive basin,” stated Miles Rideout, V.P. of Exploration. With the anticipated rebound in lithium prices driven by rising demand for EVs, Argentina Lithium is poised to benefit from this possible market correction. The company, with its strategic projects in the lithium triangle and promising exploration results, seems well-positioned to become a key player in the market and, certainly, one to watch. Featured photo by Possessed Photography on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. Benzinga has been compensated by Argentina Lithium & Energy for publicizing this content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 17, 2024 08:30 AM Eastern Daylight Time

Image

Big News For DLMI: Tokenization Pioneer Inks Deal With International Partner

Benzinga

By Johnny Rice, Benzinga Brian J. Esposito, CEO of Diamond Lake Minerals, Inc. (OTCPK: DLMI), was recently a guest on Benzinga’s All-Access and was joined by Brain Collins, CEO GlobexUS/Upstream. Diamond Lake Minerals specializes in the development and support of digital assets and SEC-registered security tokens. The company’s goal is to responsibly innovate and develop valuable traditional businesses and successfully combine them with the future of money and digital assets. Mr. Esposito and Mr. Collins spoke about their two companies’ new deal that will bring a dynamic partnership to international markets and expand access to DLMI’s exciting vision for the future of public companies. Learn more here: Featured photo by NASA on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 17, 2024 08:25 AM Eastern Daylight Time

Video Image

Findell Capital Management LLC Releases Comprehensive Research Coverage Report on ESTA: Nasdaq

Establishment Labs Holdings Inc.

New York, NY, June 17, 2024 – Findell Capital Management LLC, an investment management firm, today announced the release of a detailed Report on Establishment Labs Holdings Inc. (Nasdaq: ESTA), which can be found here. ESTA is a NASDAQ listed company, headquartered in Costa Rica, that has developed and commercialized a significantly improved breast implant. We believe ESTA stock has a credible pathway to double in the next year, with an opportunity to grow multiples beyond that with a long-term price target of +$200 versus $44.48 (6/14/2024 close). ESTA screens as expensive (7.7x sales multiple) and has a corresponding large, short interest (20%) and was also subject to a Hindenburg short report in 2022. However, Findell believes that ESTA has one of the best fundamental growth stories in the med-tech space over the next several years and 2024 will be a crucial inflection year with the launch of Motiva in the US and the roll out of Mia-Femtech abroad. ESTA has developed and commercialized a significantly improved breast implant, Motiva, that is on the cusp of being cleared by the FDA. This US launch coupled with the launch in China should allow ESTA’s base business to grow at a +30% CAGR over the next several years. The market has yet to fully appreciate how differentiated this product is from legacy products and how untenable it will be in the long run from a liability perspective for doctors to use anything but Motiva, the safest product ever developed by a large margin. We believe that Motiva’s launch in the US will be similar to how it launched in Switzerland and South Korea – it will take majority share in short order. ESTA has also developed a minimally invasive procedure called Mia-Femtech, which it has just begun to roll out. Mia is a 15-minute augmentation procedure that requires no general anesthesia and has minimum recovery time and achieves a very natural look. Given how radically different a procedure this is – both in the process and the final output – Mia could significantly expand the addressable market for augmentation – this could be to breast enhancements what Ozempic is for weight loss. With Motiva’s launch expected in early Q3 pending a site visit by the FDA and Mia-Femtech’s roll out underway, the second half of 2024 and early 2025 will provide several proof points of this burgeoning growth story and the heavily shorted stock should re-rate accordingly. Findell will be doing a live interview with SumZero at 10 AM, Monday (June 17 th ), 2024 to further discuss the story. To register – click here. Contact Details Findell Capital Management, LLC. 88 Pine Street, 22nd Fl. New York, NY 10005 info@findell.us

June 17, 2024 07:39 AM Eastern Daylight Time

Image

BestGrowthStocks.Com Issues Comprehensive Growth Drivers Analysis on BTCS Inc.

BTCS Inc.

NEW YORK, NY / News Direct/ June 17th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive evaluation of BTCS Inc. a blockchain technology-focused company. BTCS Inc. (NASDAQ: BTCS) has recently caught the attention of many investors following the announcement of the Forta Network collaboration to enhance blockchain compliance. Their Builder+ objectives as well as advancing the development of their AI-enhanced blockchain data and analytics platform. Best Growth Stock's breaks through the noise and offers a comprehensive analysis of BTCS operations, growth drivers, financials, fully diluted share structure, chart setup with support and resistance levels, potential future catalysts, and much more. Access this full analysis free: https://bestgrowthstocks.com/access-btcs-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) Access this full analysis free: https://bestgrowthstocks.com/access-btcs-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) About BTCS BTCS Inc. is a Nasdaq listed company operating in the blockchain technology sector since 2014 and is one of the only U.S. publicly traded companies with a primary focus on proof-of-stake blockchain infrastructure. Our core focus is on driving scalable growth through a diverse range of business streams leveraging and built on top of our core and proven blockchain infrastructure operations. BTCS secures and operates validator nodes on cutting-edge blockchain networks that power Web 3, earning native token rewards by staking our proof-of-stake crypto assets, with an emphasis on Ethereum. Our innovative “StakeSeeker” platform empowers crypto holders with an analytics-focused cryptocurrency dashboard. It also offers a non-custodial Staking-as-a-Service solution, enabling users to earn staking rewards, while BTCS earns a percentage of token holders’ rewards, creating the potential for scalable revenue with limited additional costs. We’ve also introduced “Builder+”, an Ethereum block builder. This technology leverages advanced algorithms to maximize profit through optimized block construction. Builder+ creates opportunities for new scalable revenue streams by being utilized by third-party nodes. For more information visit: www.btcs.com. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions.. Contact Details Best Growth Stocks Steve Macalbry Editor@bestgrowthstocks.com

June 17, 2024 07:30 AM Eastern Daylight Time

Image

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

RazorPitch CRDL

In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study topline results. The Canadian biotechnology company has captured investors’ attention this year with significant milestones achieved, including the advancement of two simultaneous Phase II clinical trials, granting of Orphan Drug Designation by the US FDA for its flagship drug CardiolRx™, and most recently, the announcement of positive topline results from their MAvERIC-Pilot study. These achievements further solidify Cardiol Therapeutics' position as a formidable player in the biotech landscape, offering renewed hope to patients suffering from debilitating rare heart conditions. Last week, Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) reported 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. The study enrolled 27 adult patients with symptomatic recurrent pericarditis at eight clinical sites across the United States, including the prominent Mayo Clinic, Cleveland Clinic, and Massachusetts General Hospital. Each patient had a high burden of disease, as reflected by both a patient-reported pain score averaging 5.8 out of 10 at baseline and the number of previous episodes of pericarditis (9 patients, or 33%, had 2 previous episodes, 9 patients, or 33%, had 3 such episodes, 4 patients, or 15%, had 4 episodes, and 5 patients, or 19%, had more than 4 episodes). The primary endpoint of the Phase II study is the change in patient-reported pericarditis pain at eight weeks, as measured by an 11-point numeric rating scale (NRS) that has been validated and applied in several clinical trials. NRS is commonly used to assess pain severity by using a scale from 0 to 10, where zero is "no pain" and 10 is "the worst pain imaginable.". Secondary endpoints include the NRS score after 26 weeks of treatment and changes in circulating levels of C-reactive protein (CRP). CRP is a commonly used marker of inflammation in patients with cardiovascular disease. MAvERIC-Pilot topline data revealed several key findings: Efficacy in Pain Reduction: Patients treated with CardiolRx™ experienced a significant reduction in the subjectively perceived pain of the pericarditis. The mean pain score dropped from 5.8 at baseline to 2.1 (64%) after eight-weeks of treatment, marking a decrease of 3.7 points on the 11-point NRS. Reduction in Inflammation: Among patients with elevated baseline CRP (≥1 mg/dL), 80% achieved normalization of CRP levels (≤0.5 mg/dL) at the end of the eight-week treatment period. The average CRP levels were reduced from 5.7 mg/dL to 0.3 mg/dL, indicating a substantial reduction in inflammation. Patient Continuation and Safety: A significantly high percentage of patients (89%) have continued into the extension phase of the study, an 18-week treatment period, suggesting that CardiolRx™ is well-tolerated. The study also confirmed that CardiolRx™ was found to be safe and well tolerated, with no significant adverse effects. David Elsley, President & CEO of Cardiol Therapeutics, expressed optimism about the potential of CardiolRx™ as a non-immunosuppressive therapeutic option for pericarditis. Mr. Elsley highlighted the drug’s comparable efficacy to existing biologic therapies used in third-line treatment of recurrent pericarditis: “ We are delighted to share the exceptional primary endpoint data from the MAvERIC-Pilot study, which demonstrated that oral administration of our small molecule CardiolRx™ led to marked reductions in pericarditis pain and inflammation, and remarkably, these reductions are comparable in magnitude to biologic therapy commonly used in third-line treatment of recurrent pericarditis. Based on the clinically meaningful impact of CardiolRx™ on the key symptom of this debilitating disease, we now anticipate that the totality of the MAvERIC-Pilot data will support advancing to a Phase III trial of CardiolRx™ designed to meet our objective of providing an accessible and non-immunosuppressive therapeutic option for thousands of pericarditis patients. ” Recurrent pericarditis, a persistent inflammation of the pericardium – the protective membrane surrounding the heart – often resurfaces following an initial episode, frequently linked to viral infections. This condition is marked by intense chest pain, shortness of breath, and debilitating fatigue, which results in significant physical limitations and a diminished quality of life for patients. With an estimated 38,000 patients in the U.S. experiencing at least one recurrence annually, and many suffering for years, the need for effective treatments is critical. Approximately 60% of patients with multiple recurrences (>1) still suffer for longer than two years, and one third are still impacted at five years. Moreover, the progressive accumulation of pericardial fluid and subsequent scarring can escalate to a life-threatening constriction of the heart, highlighting an urgent need for advancements in medical treatment and patient care protocols. The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and primarily used as a third-line intervention. However, CardiolRx™’s tolerability and side effect profile is expected to be much more favourable than the current treatment – which has risks typical of immunosuppressants. The economic burden is notable, with frequent emergency room visits and hospitalizations driving up healthcare costs. Hospitalization due to recurrent pericarditis is often associated with a 6-8-day length of stay, and the cost per stay is estimated to range between $20,000 and $30,000 in the United States. Building on the impressive topline results from the MAvERIC-Pilot study, Cardiol Therapeutics is poised to provide patients with an accessible and non-immunosuppressive treatment option for recurrent pericarditis, potentially surpassing existing therapies. These encouraging outcomes set the stage for a forthcoming Phase III trial, aiming to further validate the efficacy and safety of CardiolRx™, as Cardiol Therapeutics progresses towards commercialization. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cardiol Therapeutics to assist in the production and distribution of content related to CRDL. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 Mark@RazorPitch.com Company Website http://razorpitch.com

June 17, 2024 07:00 AM Eastern Daylight Time

BestGrowthStocks.com Issues a Comprehensive Analysis of Bitfarms Ltd. and the Recent Unsolicited Takeover Bid

Bitfarms Ltd.

NEW YORK, NY / News Direct/ June 17th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive evaluation of Bitfarms Ltd. a global vertically integrated Bitcoin mining company. Bitfarms Ltd. (NASDAQ: BITF) has recently caught the attention of many investors following an unsolicited takeover bid by Riot Blockchain. Best Growth Stock's breaks through the noise and offers a comprehensive analysis of Bitfarms operations, the takeover bid by Riot, Bitfarms financials, fully diluted share structure, chart setup with support and resistance levels, potential catalysts, and much more. Access this full analysis free: https://bestgrowthstocks.com/access-bitfarms-ltd-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) Access this full analysis free: https://bestgrowthstocks.com/access-bitfarms-ltd-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) About Bitfarms Ltd. Founded in 2017, Bitfarms is a global Bitcoin mining company that contributes its computational power to one or more mining pools from which it receives payment in Bitcoin. Bitfarms develops, owns, and operates vertically integrated mining farms with in-house management and company-owned electrical engineering, installation service, and multiple onsite technical repair centers. The Company’s proprietary data analytics system delivers best-in-class operational performance and uptime. Bitfarms currently has 12 Bitcoin mining facilities and one under development situated in four countries: Canada, the United States, Paraguay, and Argentina. Powered predominantly by environmentally friendly hydro-electric and long-term power contracts, Bitfarms is committed to using sustainable and often underutilized energy infrastructure. To learn more about Bitfarms’ events, developments, and online communities: www.bitfarms.com About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Contact Details Best Growth Stocks Steve Macalbry Editor@bestgrowthstocks.com

June 17, 2024 07:00 AM Eastern Daylight Time

Image

All Industries

Cardano, Raboo and Ordi are Trending This Week, Find Out Why

Hoffman Financial Group Joins Forces with AmeriLife’s Brookstone Capital Management

ATFX Integrates PriceOn™ from TraderTools to Enhance Global Group Trading Efficiency

Market Forecasts Hint At A Lithium Revival: Could This Be A Golden Opportunity For Argentina Lithium (OTCQX: LILIF) And Other Miners?

Big News For DLMI: Tokenization Pioneer Inks Deal With International Partner

Findell Capital Management LLC Releases Comprehensive Research Coverage Report on ESTA: Nasdaq

BestGrowthStocks.Com Issues Comprehensive Growth Drivers Analysis on BTCS Inc.

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

BestGrowthStocks.com Issues a Comprehensive Analysis of Bitfarms Ltd. and the Recent Unsolicited Takeover Bid